Table 2. Table demonstrating proportion of patients (%) treated with isotonic or hypotonic riboflavin in whom Kmax and Kmean regressed, progressed, or remained stable at 9 and 12 months from baseline.

	Isotonic				Hypotonic
	9 Months		12 Months		9 Months		12 Months
	Kmax	Kmean	Kmax	Kmean	Kmax	Kmean	Kmax	Kmean
Regressed by 1D or more	40.5	19.6	39.7	15.3	66.7	33.3	58.3	16.7
Progressed by 1D or more	24.3	13.0	15.9	18.8	33.3	33.3	16.7	25.0
Remained stable (progressed or regressed by less than 1D)	35.2	67.4	44.4	65.9	0.0	33.3	25.0	58.3